Amgen TEPEZZA Subcutaneous Trial Shows Strong Phase 3 Results
Thousand Oaks, California, USA, April 6, 2026 Phase 3 Success Expands TEPEZZA Treatment Options In a major advancement for...
biologics
Advertisement
GC Biopharma Enhances IVIG Safety with FXI Detection
YONGIN, South Korea, April 6, 2026 GC Biopharma has announced a major advancement in intravenous immunoglobulin (IVIG) safety monitoring...
Earendil Labs Advances HXN-1001 Into Phase IIa Trial
WILMINGTON, Del., April 2, 2026 Earendil Labs, an AI-driven biotechnology company, has announced that the first patient has been...
Merck Partners Infinimmune in $838M Antibody Discovery Deal
RAHWAY, N.J., USA — March 31, 2026 Merck & Co. has entered into a strategic antibody discovery collaboration with...
Savara Advances MOLBREEVI EMA Review for Rare Lung Disease
LANGHORNE, Pa., March 30, 2026 Savara Inc. has achieved a major regulatory milestone as the European Medicines Agency (EMA)...
Advertisements
Novartis Acquires Excellergy in $2B Allergy Innovation Deal
Basel, Switzerland | March 27, 2026 Strategic Acquisition Strengthens Allergy Leadership Novartis has announced a major strategic move to...
FDA Approves AVLAYAH for Hunter Syndrome Treatment
SOUTH SAN FRANCISCO, Calif., March 25, 2026 In a landmark regulatory milestone, Denali Therapeutics announced that the U.S. Food...
Dupixent Approved in Japan for Rare Skin Disease
PARIS, FRANCE & TARRYTOWN, NEW YORK, USA | March 24, 2026 Sanofi and Regeneron have announced that Japan’s Ministry...
Apogee Therapeutics Prices $350M Public Offering
SAN FRANCISCO & BOSTON, USA | March 24, 2026 Apogee Therapeutics, Inc. has successfully announced the pricing of its...
Embecta Acquires Owen Mumford to Expand Drug Delivery
Parsippany, New Jersey, USA | March 19, 2026 Embecta Corp. has announced a definitive agreement to acquire Owen Mumford...
Advertisement
